Clinical trial
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple…
NCT00151203 · Weill Medical College of Cornell University, Other · Completed
Key facts
| NCT number | NCT00151203 |
|---|---|
| Title | Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma |
| Official title | A Phase II Study of Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) for Newly Diagnosed Subjects With Multiple Myeloma |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Clarithromycin, Lenalidomide, Dexamethasone |
| Enrollment | 50 |
| Start date | Dec 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Sep 29, 2020 |
| First posted | Sep 8, 2005 |
| Last update posted | May 27, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: